Report error Found 125 of ic50 data for polymerid = 1308
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Human)
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
